Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer
使用蛋白质翻译延伸抑制剂 SVC112 靶向治疗头颈鳞状细胞癌中的 eEF2
基本信息
- 批准号:10268847
- 负责人:
- 金额:$ 36.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectBiological AssayBiological MarkersCancer ModelCancer PatientCancer PrognosisCancer cell lineCell CommunicationCell CycleCell modelCellsClinical TrialsColoradoCompanionsComplexCyclin D1DataDiseaseDoseDrug KineticsDrug resistanceEvaluationFDA approvedFRAP1 geneFailureFibrinogenGenesGoalsGrowthHead and Neck CancerHead and Neck Squamous Cell CarcinomaHead and neck structureHomeHumanHuman PapillomavirusHypoxiaImmuneImmune EvasionImmune TargetingImmunityImmunologic SurveillanceImmunotherapyIn VitroInfiltrationInternal Ribosome Entry SiteLigandsMalignant NeoplasmsMeasuresMediatingMessenger RNAMinorityModalityModelingMolecular TargetMusMutationOncogenicOncoproteinsOutcomePapillomavirus Transforming Protein E6Pathway interactionsPatientsPharmaceutical PreparationsPharmacologyPredictive Value of TestsPredispositionProductionPropertyProtein BiosynthesisProteinsProteomeProteomicsProto-Oncogene Proteins c-mycRadiation therapyRelapseReportingResistanceRestRibosomesSamplingSignal TransductionStressT-LymphocyteTestingTherapeuticTherapeutic IndexTissue BanksTissuesToxic effectToxicity TestsTranslationsTreatment EfficacyTreatment FailureTumor BankTumor-infiltrating immune cellsWorkbasecancer cellcancer therapyefficacy testingfitnessgene producthumanized mousein vivoin vivo Modelinhibitor/antagonistmouse modelneoplastic cellnovel therapeuticspatient derived xenograft modelpembrolizumabpredictive markerprogrammed cell death ligand 1programmed cell death protein 1protein expressionribosome profilingsmall moleculestemnesssynergismtooltranscription factortumortumor growthtumor microenvironmenttumor progression
项目摘要
SUMMARY. Radiation therapy (RT) and immunotherapy with PD-1 inhibitors are used in early and relapsed
head and neck squamous cell cancers (HNSCC), respectively; RT failures are common, and most patients do
not respond to PD-1 inhibition. Both impact the tumor microenvironment (TME), but studying the TME is limited
by the availability of models with human immune cells. PI3K/mTOR signaling regulates protein synthesis through
transcription factors such as Myc or SOX2, that dictate growth, invasion, and drug resistance in HNSCC. SVC112
is a fully synthetic small molecule that inhibits protein synthesis at the elongation step by inhibiting eEF2. SVC112
had greater effect on cancer over non-cancer cells, and was more potent and selective than homoharringtonin
(HHT), an FDA-approved translation elongation inhibitor. Cancer cells had higher eEF2 than non-cancer cells,
and the most susceptible strain had the highest eEF2 expression. SVC112 depleted SOX2, Myc, and Cyclin D1
in HNSCC cells at concentrations that had minimal effect on the rest of the proteome. SVC112 decreased
spheres in vitro, reduced tumor growth in vivo in patient-derived xenografts (PDX), and induced tumor regression
when given with RT in three out of four PDX models. SVC112 also reduced the E6 oncoprotein in human
papillomavirus-driven cells. Lastly, SVC112 decreased PD-1 ligand (PD-L1) resulting in decreased PD-L1:PD-1
interactions leading to increased sphere T cell invasion, while having no effect on T cell fitness or function. Thus,
SVC112 can target multiple key pathways (SOX2, Myc, PD-L1), and can influence the TME to reverse immune
evasion. To test SVC112’s therapeutic potential in HNSCC, several unique tools will be used including 1) spheres
containing cancer cells and T cells (iSpheres) that enable studying TME interactions and immunotherapy in vitro,
2) syngeneic mouse models of HNSCC, and 3) humanized mouse (HM) models, developed by the PI, that enable
studying TME interactions and immunotherapy in vivo. The hypothesis that SVC112’s discriminating effect is
due to selective depletion of key proteins will be tested by ribosome profiling (to identify mRNA targets) and
proteomics analysis (to identify proteins targets). Then, we will test the mechanism of SVC112 synergy with RT,
and if the modulation of the TME by SVC112 will further enhance RT efficacy. Lastly, the hypothesis that
reduction of PD-L1 by SVC112 in HNSCC will alter the tumor-immune interaction will be tested by defining the
effect of SVC112 on the expression of proteins critical for the TME, T cell tumor infiltration, and cancer-immune
crosstalk. The effect of SVC112 on T cell fitness and function will be examined, aiding SVC112 translation. We
will assess SVC112 and PD-1 inhibition in iSphere and HM models, and explore their efficacy when both are
combined. Lastly, we will test the predictive value of eEF2 in SVC112 susceptibility, and we will assess eEF2
expression in human tumors, to enable identifying a companion biomarker to SVC112, using a HNSCC tissue
bank with 1,250 patient cases. This project will propel the translation of SVC112, a drug discovered in Colorado,
by dissecting the basis for its effect, studying its toxicity, and testing predictive biomarkers to aid clinical trials.
总结。早期和复发患者采用放射治疗(RT)和PD-1抑制剂免疫治疗
分别为头颈部鳞状细胞癌(HNSCC);RT失败很常见,大多数患者也是如此
对PD-1抑制无反应。两者都影响肿瘤微环境(TME),但对TME的研究有限
人类免疫细胞模型的可获得性。PI3K/mTOR信号转导途径调节蛋白质合成
转录因子,如Myc或SOX2,决定HNSCC的生长、侵袭和耐药性。SVC112
是一种完全合成的小分子,通过抑制eEF2来抑制伸长阶段的蛋白质合成。SVC112
对癌症的影响比非癌细胞更大,比高三尖杉酯碱更有效和更有选择性
(HHT),一种FDA批准的翻译延长抑制剂。癌细胞的eEF2高于非癌细胞,
最敏感品系的eEF2表达水平最高。SVC112耗尽SOX2、Myc和Cyclin D1
在HNSCC细胞中,对蛋白质组其余部分影响最小的浓度。SVC112减少
体外球体,减少患者来源的异种移植(PDX)体内的肿瘤生长,并诱导肿瘤消退
当给予RT时,四个PDX模型中有三个。SVC112还降低了人类E6癌蛋白
乳头瘤病毒驱动的细胞。最后,SVC112使PD-1配体(PD-L1)减少,导致PD-L1:PD-1减少
相互作用导致球形T细胞侵袭增加,而对T细胞健康或功能没有影响。因此,
SVC112可以靶向多个关键通路(SOX2、Myc、PD-L1),并可影响TME逆转免疫
逃避。为了测试SVC112的S在鼻咽癌中的治疗潜力,将使用几种独特的工具,包括1)球体
含有癌细胞和T细胞(ISphes),能够在体外研究TME相互作用和免疫治疗,
2)HNSCC同基因小鼠模型,3)PI开发的人源化小鼠(HM)模型,使
研究TME相互作用和体内免疫治疗。SVC112的S辨证作用为
由于关键蛋白的选择性耗尽,将通过核糖体图谱(以确定mRNA靶标)和
蛋白质组学分析(以确定蛋白质靶标)。然后,我们将测试SVC112与RT的协同作用机制,
而SVC112对TME的调节是否会进一步增强RT的疗效。最后,假设
在HNSCC中,SVC112降低PD-L1会改变肿瘤-免疫相互作用,将通过定义
SVC112对TME、T细胞肿瘤侵袭及肿瘤免疫关键蛋白表达的影响
相声。我们将研究SVC112对T细胞适合性和功能的影响,以帮助翻译SVC112。我们
将在IVERE和HM模型中评估SVC112和PD-1的抑制作用,并探索当两者都是
加在一起。最后,我们将测试eEF2在SVC112易感性中的预测价值,并评估eEF2
在人类肿瘤中表达,以便能够使用HNSCC组织识别SVC112的伴随生物标记物
银行有1,250例患者。该项目将推动在科罗拉多州发现的药物SVC112的翻译,
通过剖析其效果的基础,研究其毒性,并测试预测生物标记物以帮助临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Antonio Jimeno其他文献
Antonio Jimeno的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Antonio Jimeno', 18)}}的其他基金
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer
使用蛋白质翻译延伸抑制剂 SVC112 靶向治疗头颈鳞状细胞癌中的 eEF2
- 批准号:
10477463 - 财政年份:2021
- 资助金额:
$ 36.67万 - 项目类别:
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer
使用蛋白质翻译延伸抑制剂 SVC112 靶向 eEF2 治疗头颈鳞状细胞癌
- 批准号:
10704601 - 财政年份:2021
- 资助金额:
$ 36.67万 - 项目类别:
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112
使用延伸抑制剂 SVC112 靶向唾液腺癌中的致癌 Myb 融合
- 批准号:
10368161 - 财政年份:2021
- 资助金额:
$ 36.67万 - 项目类别:
Targeting oncogenic Myb fusions in salivary gland cancer with the elongation inhibitor SVC112
使用延伸抑制剂 SVC112 靶向唾液腺癌中的致癌 Myb 融合
- 批准号:
10592292 - 财政年份:2021
- 资助金额:
$ 36.67万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 36.67万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 36.67万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 36.67万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 36.67万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 36.67万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 36.67万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 36.67万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 36.67万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 36.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 36.67万 - 项目类别:
Studentship